Genmab (GMAB) announced that it will discontinue further clinical development of acasunlimab. This decision does not impact Genmab’s full-year 2025 financial guidance. “After careful consideration, we have decided to discontinue the acasunlimab program. Although the data have been encouraging, the compelling opportunities we see in our late-stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina-S, and we remain committed to executing these programs with speed and rigor,” said Jan van de Winkel, CEO, Genmab.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know
- Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment
- Genmab’s Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties
- Genmab’s New Phase 3 Study: A Potential Game-Changer in Ovarian Cancer Treatment
- Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio